癌症
免疫检查点
免疫系统
PD-L1
效应器
癌症研究
癌细胞
转录因子
癌症免疫疗法
T细胞
生物
免疫疗法
免疫
免疫学
基因
遗传学
作者
Lin Qu,Jiakang Jin,Jianan Lou,Chao Nan Qian,Jinti Lin,Ankai Xu,Bing Liu,Man Zhang,Huimin Tao,Wei Yu
标识
DOI:10.1007/s00262-022-03176-7
摘要
As the main immune checkpoint, PD-L1-PD-1 interaction plays a critical role in the dysregulation of effector T cells, which contributes to the failure of Chimeric Antigen Receptor T-cell (CAR-T) and other immunotherapies. Presently, most research focuses on the extracellular function of PD-L1. Membrane PD-L1 can interact with its receptor PD-1 and decrease T cell-induced cancer immunity. However, the function of PD-L1 in cancer cells is still unclear. Recent studies have shown the separated clinical significance of PD-L1 expression in various cancer types, showing the complexity of PD-L1 in cancer cell regulation. As a novel regulatory pathway, the nuclear translocation of PD-L1 in cancer cells receives more attention. Results of these preclinical studies demonstrated that nuclear PD-L1 has an essential role in cancer development and other immune checkpoint molecules transcription. Herein, we summarized the mechanisms involved in PD-L1 nuclear transportation and identify the key regulatory factors in this process. Furthermore, we also summarize the function of nuclear PD-L1 in cancer immunity. These findings suggested the novel PD-L1 regulation in cancer development, which showed that nuclear PD-L1 is a potential therapeutic target in future cancer therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI